ACA
TARA icon

Acorn Capital Advisors’s Protara Therapeutics TARA Stock Holding History

Acorn Capital Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69M Hold
1,752,115
– – 1.83% 11
2026
Q1 		$9.13M Hold
1,752,115
– – 2.59% 10
2025
Q4 		$9.34M Hold
1,752,115
– – 3.16% 10
2025
Q3 		$7.62M Hold
1,752,115
– – 3.87% 9
2025
Q2 		$5.31M Buy
1,752,115
+472,315
+37% +$1.63M 3.47% 11
2025
Q1 		$5.45M Hold
1,279,800
– – 3.64% 8
2024
Q4 		$6.76M Buy
+1,279,800
New +$4.13M 3.64% 10

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Acorn Capital Advisors's TARA Position: Q2 2026 in Review

Acorn Capital Advisors held its Protara Therapeutics (TARA) position steady in Q2 2026 at 1,752,115 shares worth $6.69M. The position accounts for 1.83% of the portfolio, ranked #11.

Acorn Capital Advisors first reported a position in TARA in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.34M in Q4 2025. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Acorn Capital Advisors held 1,752,115 shares of Protara Therapeutics worth $6.69M as of Q2 2026.
  • Acorn Capital Advisors left its Protara Therapeutics share count unchanged in Q2 2026.
  • Protara Therapeutics made up 1.83% of Acorn Capital Advisors's portfolio in Q2 2026, its #11 holding.
  • Acorn Capital Advisors first reported a position in Protara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Acorn Capital Advisors's Protara Therapeutics position peaked at $9.34M in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.